Borrelia WB IgG: A Key Biomarker in Lyme Disease Diagnostics
The Borrelia Western Blot IgG (Immunoglobulin G) is a vital component in the diagnostic process for Lyme disease, an infection caused by the bacterium Borrelia burgdorferi. IgG antibodies are part of the body’s adaptive immune response and typically develop weeks to months after initial infection, indicating either past exposure or a current, longer-term immune response. Because Lyme disease is a complex, multi-stage illness with varying symptomatology depending on the stage, the IgG Western Blot test provides valuable insights, especially in patients with symptoms that suggest chronic or late-stage infection.
Understanding Borrelia WB IgG in the Context of Lyme Disease
In the typical two-step testing approach recommended by the CDC, an enzyme-linked immunosorbent assay (ELISA) is conducted first to screen for Lyme disease. If this test is positive or equivocal, a Western Blot test is used to confirm the diagnosis, distinguishing between the presence of IgG and IgM antibodies to Borrelia burgdorferi. For an IgG Western Blot to be considered positive, it generally requires reactivity to at least 5 out of 10 specified protein bands. These bands represent different proteins of Borrelia burgdorferi, with each band corresponding to a different molecular weight protein such as P41 (flagellin), OspC, and P100. The presence of these antibodies suggests that the immune system has previously encountered the bacterium and has generated a memory response, which is characteristic of a later or persistent infection.
IgG antibodies play a critical role in long-term immunity and are often present in the bloodstream long after the initial infection. As a result, a positive IgG test does not necessarily mean that the infection is active but does indicate past exposure to the Lyme-causing bacteria. Therefore, a positive Borrelia WB IgG result, when combined with clinical symptoms, provides strong evidence that a patient may be dealing with Lyme disease. However, clinicians consider this result alongside the IgM test and clinical history to differentiate between an active infection and residual antibodies from a past infection.
The Role of P100 in the IgG Panel
The P100 antigen, a 100 kDa protein specific to Borrelia burgdorferi, is often included in the Western Blot IgG panel and can be particularly indicative of later-stage Lyme disease or a prolonged immune response. P100 is one of several proteins the immune system may recognize and produce antibodies against over time, though it tends to become detectable after the infection has persisted for an extended period. Its presence, alongside other IgG bands, supports the likelihood of a more established infection. Because P100 reactivity usually correlates with the later stages of Lyme disease, it’s often absent in early infection, making it a specific marker in cases where Lyme disease has progressed.
While P100 is informative, it does not stand alone as a diagnostic criterion. A positive P100 result should be assessed with other reactive bands in the IgG Western Blot, helping confirm the immune system’s response to various Borrelia antigens over time. Clinically, this may also point to cases where a patient has been infected but was either undiagnosed or untreated in the early stages, allowing the infection to advance. As such, P100's presence on the IgG panel supports the likelihood of a persistent or chronic infection rather than a recent, acute exposure.
Borrelia WB IgM and Its Relationship with IgG and P100
The Borrelia Western Blot IgM test detects Immunoglobulin M (IgM) antibodies, which generally develop early after infection and are considered markers of acute or recent infection. In cases of new Lyme disease infection, IgM antibodies tend to appear within 2 to 4 weeks and may persist for several months. A positive IgM result typically requires reactivity to 2 of 3 bands, focusing on different proteins than the IgG panel. The IgM Western Blot helps identify an active immune response early in infection, which is particularly useful for diagnosing Lyme disease in patients with recent exposure or early-stage symptoms.
When both IgM and IgG antibodies are positive, it may indicate an ongoing or progressive infection where the immune response is evolving. Over time, as the immune system's response matures, IgM antibodies often decline, while IgG antibodies, such as those targeting P100, become more prominent. Therefore, in chronic or late-stage Lyme disease, IgM antibodies may no longer be present, while IgG antibodies, including those directed at P100, reflect an established immune response.
The relationship between IgM and IgG is important diagnostically because it indicates different stages of infection. A positive IgM with a negative IgG generally points to early Lyme disease, while a positive IgG without IgM could indicate a past infection or a later stage of Lyme. If both IgM and IgG are positive, it may reflect an ongoing infection or the body's continued immune response. In cases where P100 is also positive on the IgG panel, it can signal that the infection is long-standing or that there has been prolonged immune activation, which can be especially relevant for patients presenting with persistent or chronic symptoms. This combination of results can help clinicians decide whether treatment is necessary and guide the approach to patient management.
Clinical Interpretation of Borrelia WB IgG, IgM, and P100 Results
Interpreting these test results can be complex. If a patient has a positive IgM but a negative IgG, it often signifies a recent infection, and treatment may be pursued to prevent the disease from progressing. However, a positive IgG without IgM generally suggests past exposure, possibly without an active infection. In cases where P100 is positive, it may indicate that the immune system had prolonged exposure to Borrelia burgdorferi, potentially pointing toward a late-stage or persistent infection. This is particularly relevant for patients with ongoing symptoms that resemble late-stage Lyme disease or post-treatment Lyme disease syndrome (PTLDS).
The combination of a positive IgG, including reactivity to P100, with a negative IgM can sometimes be observed in patients who have had Lyme disease in the past and now have lasting antibodies. However, clinicians consider these findings alongside symptom history, exposure risk, and additional diagnostic tools to determine whether the infection is active or if lingering antibodies are responsible for the immune response. Persistent antibodies, especially in chronic or late Lyme disease, can result in ongoing immune reactivity even after treatment, which may contribute to symptoms.
Conclusion
The Borrelia WB IgG test, particularly in conjunction with IgM and markers like P100, is a crucial tool in the diagnosis and management of Lyme disease. The presence of IgG antibodies suggests past exposure or a longer-term immune response, with P100 adding significant diagnostic value by indicating the possibility of chronic infection. Meanwhile, the IgM test is invaluable for identifying early-stage Lyme, offering insight into recent exposure. Together, these biomarkers provide a comprehensive picture of the infection stage, allowing clinicians to tailor treatment approaches. However, given the complexities of Lyme disease, these results are best interpreted with clinical evaluation, ensuring that a patient’s history, symptomatology, and test results align for an accurate diagnosis.
Borrelia WB IgG
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.